Novartis plans strategy to offset high cost of new heart failure drug

Novartis CEO Joe Jimenez told the Wall Street Journal that the company is considering offering add-on healthcare services to insurers concerned with the high costs of its newest drug.

On July 7, the FDA approved sacubitril/valsartan (Entresto), a twice-daily oral medication to treat patients with heart failure and reduced ejection fraction. At $12.50 per patient per day, the medication costs much more than older drugs, which cost less than a dollar per dose. Read more at the link below: